Business Description
Ironwood Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US46333X1081
Share Class Description:
IRWD: Class ACompare
Compare
Traded in other countries / regions
IRWD.USAI76.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2010-02-03Description
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | -1.02 | |||||
| Debt-to-Equity | -1.79 | |||||
| Debt-to-EBITDA | 10.04 | |||||
| Interest Coverage | 2.19 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -5.35 | |||||
| Beneish M-Score | -4.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.4 | |||||
| 3-Year EBITDA Growth Rate | -23.9 | |||||
| 3-Year EPS without NRI Growth Rate | -67.5 | |||||
| 3-Year FCF Growth Rate | -26 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -18.59 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.94 | |||||
| 9-Day RSI | 50.78 | |||||
| 14-Day RSI | 49.9 | |||||
| 3-1 Month Momentum % | -57.51 | |||||
| 6-1 Month Momentum % | -86.48 | |||||
| 12-1 Month Momentum % | -90.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.34 | |||||
| Quick Ratio | 3.34 | |||||
| Cash Ratio | 2.26 | |||||
| Days Sales Outstanding | 75.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | 105.27 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 23.2 | |||||
| Net Margin % | -10.18 | |||||
| EBITDA Margin % | 18.78 | |||||
| FCF Margin % | 24.68 | |||||
| ROA % | -8.5 | |||||
| ROIC % | -34.59 | |||||
| 3-Year ROIIC % | 221.59 | |||||
| ROC (Joel Greenblatt) % | 111.77 | |||||
| ROCE % | 19.65 | |||||
| Years of Profitability over Past 10-Year | 5 | |||||
| Moat score | 5 | |||||
| Tariff score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 4.01 | |||||
| Price-to-Owner-Earnings | 2.49 | |||||
| PS Ratio | 0.36 | |||||
| Price-to-Free-Cash-Flow | 1.63 | |||||
| Price-to-Operating-Cash-Flow | 1.63 | |||||
| EV-to-EBIT | 10.48 | |||||
| EV-to-EBITDA | 10.13 | |||||
| EV-to-Revenue | 1.9 | |||||
| EV-to-FCF | 7.71 | |||||
| Price-to-GF-Value | 0.09 | |||||
| Price-to-Projected-FCF | 0.1 | |||||
| Price-to-Median-PS-Value | 0.08 | |||||
| Earnings Yield (Greenblatt) % | 9.54 | |||||
| FCF Yield % | 65.51 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers